Dr. Yap specializes in the management of urologic cancers (kidney, bladder, prostate, and testes). His practice includes open, minimally invasive and robotic surgical approaches. He believes in a collaborative and personalized approach to provide the best possible care to each of his patients.
His research interests include assessing treatment strategies in the management of kidney cancers. He is also interested in assessing the quality of care and the effectiveness of our treatments in the management of all urologic cancers.
UC Davis Comprehensive Cancer Center
2279 45th Street, 2nd Floor
Sacramento, CA 95817
M.Sc., University of Toronto, Toronto, ON Canada, 2013
B.S., University of Michigan, Ann Arbor, MI, 2000
Royal College of Physicians of Canada,
American Urologic Association
Canadian Urologic Association
Society of Urologic Oncology
Select Honors and Awards:
Pillsbury Award-Most Distinguished Undergraduate Dissertation in Psychology, University of Michigan, 2000
Earl F. Nation Resident Scholarship (Western section AUA), 2007
Earl F. Nation Resident Scholarship (Western section AUA), 2008
N. California Urological Resident Research Seminar - First place - Basic science, 2009
Gerald P. Murphy Memorial Scholar (AUA), 2009
Charles J. Robson Research Day (Toronto, ON, Canada) - Second place - clinical research, 2011
Amgen Canada Fellowship (AUA), 2011
Health Policy, Management, and Evaluation Research Day - First place poster - health services research, 2011
Canadian Urologic Association Meeting – Five-star poster award - general oncology, 2011
Resident Teaching Award, University of Toronto, 2013
Select Recent Publications:
Yang JC, Bai L, Yap S, Gao AC, Kung HJ, Evans CP. Effect of the specific Src family kinase inhibitor Saracatinib on osteolytic lesions using the PC-3 bone model. Mol Cancer Ther. 2010, Jun, 9(6): 1629-37.
Yap SA, Schupp CW, Chamie K, Evans CP, Koppie TM. The Impact of Age on Transitional Cell Carcinoma of the Upper Urinary Tract: Presentation, Treatment, and Outcomes. Urology<.i>. 2011, May, 78(1): 87-92.
Yap SA, Alibhai SMH, Abouassaly R, Timilshina N and Finelli A. Do we continue to unnecessarily perform ipsilateral adrenalectomy at the time of radical nephrectomy? – A population-based study. J Urol. 2012, Feb, 187(2): 398-404.
Jewett M, Finelli A, Kollmannsberger C, et al. Management of kidney cancer: Canadian kidney cancer forum consensus update 2011. Can Urol Assoc J. 2012, Feb, 6(1):16-22.
Margel D, Yap SA, Lawrentschuk N, Klotz L, Haider M, Hersey K, Finelli A, Zlotta A, Trachtenberg J, and Fleshner N. Impact of multiparametric endorectal coil prostate MRI on disease reclassification among active surveillance candidates - a prospective cohort study. J Urol. 2012, Apr, 187(4): 1247-52.
Venkateswaran S, Margel D, Yap SA, Hersey K, Yip P, Fleshner NE. Comparison of serum testosterone levels in prostate cancer patients receiving LHRH agonist therapy with or without the removal of the prostate. CUAJ. 2012, Jun, 6(3):183-6.
Yap SA, Alibhai S, Finelli A. A practical review of the diagnosis and management of small renal masses. J of Current Clinical Care. August 28, 2012.
Yap SA, Stakhovskyi O, Finelli A. The emerging role of percutaneous biopsy in diagnosis and management of small renal masses. Current Opinion in Urology. 2012, Sept, 22(5):360-4.
Yap SA, Horovitz D, Alibhai SMH, Abouassaly R, Timilshina N and Finelli A. Predictors of early mortality after radical nephrectomy with renal vein or IVC thrombectomy – A population based study. BJUI. April 2012.
Yap SA, Alibhai SMH, Abouassaly R, Timilshina N, Margel D, Finelli A. Ipsilateral adrenalectomy at the time of radical nephrectomy impacts overall survival? BJUI